Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 13/20 | 0.67 |
| ▸ | MAPT | P10636 | 11/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.66 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13068898 | 0.93 | ACHE (0.61) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL8256686 | 0.91 | L3MBTL1 (0.72) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13433992 | 0.86 | L3MBTL1 (0.53) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3069940 | 0.86 | L3MBTL1 (0.65) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL10107391 | 0.85 | L3MBTL1 (0.70) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL11890493 | 0.85 | L3MBTL4 (0.66) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13433961 | 0.84 | L3MBTL1 (0.50) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL12697215 | 0.84 | L3MBTL4 (0.64) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL2002013 | 0.84 | L3MBTL1 (0.65) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13962113 | 0.84 | L3MBTL4 (0.64) | L3MBTL1MAPTHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022268154-A1 | NEW ANTI-HEPATITIS B COMPOUND | 上海齐鲁制药研究中心有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| US-8338624-B2 | Isoflavone derivatives and uses thereof | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2012-12-25 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20100069478-A1 | ISOFLAVONE DERIVATIVES AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO, LTD. (IL) | 2010-03-18 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, TRPV1, KCNJ1 | L3MBTL1 4783/4885MAPT 2574/4885HPGD 947/4885 |
| US-20100069478-A1 | ISOFLAVONE DERIVATIVES AND USES THEREOF | SHBG, CYP19A1, GPER1 | L3MBTL1 4608/4885MAPT 4707/4885HPGD 525/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | L3MBTL1 4783/4885MAPT 2574/4885HPGD 947/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | L3MBTL1 4426/4885MAPT 620/4885HPGD 375/4885 |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | KCNJ1, KCNJ2, KCNJ11 | L3MBTL1 4347/4885MAPT 1992/4885HPGD 758/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | L3MBTL1 3531/4885MAPT 3478/4885HPGD 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.